Table 2.
Feasibility and response evaluation data.
| Procedures | |||
| Total no. PIPAC procedures | 129 | ||
| PIPACs/pt, mean (SD) | 3.66 (1.95) | ||
| PIPACs/pt, median (range) | 3 (1–9) | ||
| Technical aspects | PIPAC 1 (n = 35) | PIPAC 3 (n = 27) | |
| Intraperitoneal access, no. patients (%) | 35 (100%) | 27 (100%) | |
| Procedure time, minutes (range) | 100 (71–156) | 92 (77–125) | |
| Days of admission, median (range) | 1 (1–4) | 1 (0–3) | |
| Discharge day 0/1, no. patients (%) | 28 (80%) | 24 (89%) | |
| Pain/PONV | |||
| Postoperative pain*, median (range) | 3 (0–10) | 3 (0–7) | |
| Postoperative nausea, no. patients | |||
| None | 24 | 14 | |
| Mild | 2 | 4 | |
| Moderate | 1 | 3 | |
| Severe | 8 | 5 | |
| Postoperative vomiting, no. patients | |||
| None | 26 | 18 | |
| 1 vomit | 2 | 1 | |
| 2–3 vomits | 3 | 2 | |
| >3 vomits | 4 | 5 | |
| Response evaluation | PIPAC 1 | PIPAC 3 | |
| PRGS, mean (SD) | 2.05 (0.66) | 1.54 (0.52) |
p = 0.0006 |
| PRGS, maximum value | 4 | 3 | |
| PRGS improvement, patients (%) | 18/27 (67%) | ||
| Malignant cells in peritoneal lavage | 13/22 (59%) | 9/22 (41%) | |
| Conversion nonmalignant → malignant | 1/22 (4.5%) | ||
| Conversion malignant → nonmalignant | 5/22 (23%) | ||
| No conversion | 8/22 (36%) |
*
Visual Analog Scale 1–10.
PIPAC, pressurized intraperitoneal aerosol chemotherapy; PONV, postoperative nausea and vomiting; PRGS, peritoneal regression grading score; Pt, patient; SD, standard deviation.